Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Sacituzumab govitecan-hziy in Liver metastases: NCT07151586 Clinical Landscape Report 2026
28 September 2026
NCT07151586 clinical landscape for Liver metastases: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pembrolizumab biosimilar(Henlius) in Renal Cell Carcinoma: NCT07160335 Clinical Landscape Report 2026
28 September 2026
NCT07160335 clinical landscape for Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Anlotinib Dihydrochloride in Locally Advanced Soft Tissue Sarcoma: NCT07156643 Clinical Landscape Report 2026
28 September 2026
NCT07156643 clinical landscape for Locally Advanced Soft Tissue Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Vebreltinib in Clear Cell Sarcoma: NCT07153887 Clinical Landscape Report 2026
28 September 2026
NCT07153887 clinical landscape for Clear Cell Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Omacetaxine Mepesuccinate in Non-Hodgkin's lymphoma refractory: NCT07159906 Clinical Landscape Report 2026
28 September 2026
NCT07159906 clinical landscape for Non-Hodgkin's lymphoma refractory: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…
9 min read
Anti-EBV Autologous TCR-T Cell(Shanghai First People's Hospital) in Peripheral T-Cell Lymphoma: NCT07162012 Clinical Landscape Report 2026
28 September 2026
NCT07162012 clinical landscape for Peripheral T-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pirfenidone in Advanced Triple-Negative Breast Carcinoma: NCT07161791 Clinical Landscape Report 2026
28 September 2026
NCT07161791 clinical landscape for Advanced Triple-Negative Breast Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development w…
9 min read
Envafolimab in Advanced Renal Cell Carcinoma: NCT07159191 Clinical Landscape Report 2026
28 September 2026
NCT07159191 clinical landscape for Advanced Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Anti-CD19, Anti-CD20 CAR T Cells(Universitätsspital Basel) in B-Cell Leukemia: NCT07166549 Clinical Landscape Report 2026
28 September 2026
NCT07166549 clinical landscape for B-Cell Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Rinatabart Sesutecan in Recurrent Endometrial Cancer: NCT07166094 Clinical Landscape Report 2026
28 September 2026
NCT07166094 clinical landscape for Recurrent Endometrial Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Everolimus in Advanced Renal Cell Carcinoma: NCT07165418 Clinical Landscape Report 2026
28 September 2026
NCT07165418 clinical landscape for Advanced Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Belzutifan in Von Hippel-Lindau Disease: NCT07167329 Clinical Landscape Report 2026
28 September 2026
NCT07167329 clinical landscape for Von Hippel-Lindau Disease: endpoints, sponsor, phase, geography, readouts, asset context and development white space.